Amgen, Inc. (NASDAQ:AMGN) is working on multiple aspects of latest biotechnology in order to develop novel drugs for rare and life-threatening diseases. The drug pipeline has different types of investigational molecules that are undergoing clinical phases to prove their vitality in the management and treatment of diversified ailments.
In January 2015, Amgen CEO Robert A Bradway said: “Excitement and momentum are palpable at Amgen as we focus on genetic validation of high potential biological targets, next-generation biomanufacturing and transformational activities that increases our agility and help us to deliver new and meaningful medicines to patients.”
In January 2015, Amgen CEO Robert A Bradway said: “Excitement and momentum are palpable at Amgen as we focus on genetic validation of high potential biological targets, next-generation biomanufacturing and transformational activities that increases our agility and help us to deliver new and meaningful medicines to patients.”
